Market Signal Briefing

Key Takeaways INCY gained EU approval for Zynyz with chemotherapy as first-line treatment for metastatic or recurrent SCAC.Zynyz cut risk of progression or death by 37% in POD1UM-303, with 9.3-month median PFS vs 7.4 for placebo.Incyte is expanding its oncology portfolio as Zynyz complements revenue driver Jakafi. Incyte (INCY - Free Report) recently announced that the European Commission has approved a label expansion of oncology drug Zynyz (retifanlimab) for a second indication.

The drug is now approved in the EU in combination with chemotherapy for the first-line treatment of adults with metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC).

Zynyz is a PD-1 immune checkpoint inhibitor designed to help the immune system recognize and attack cancer cells.

The decision marks the first systemic treatment approved in Europe for newly diagnosed patients with advanced SCAC and expands Incyte’s growing oncology portfolio.

Shares of Incyte have gained 34.4% in the past year compared with the industry’s 12.5% growth.

Image Source: Zacks Investment Research

More on INCY’s ZynyzThe EC approval was based on results from the late-stage POD1UM-303 (InterAACT2) study, which evaluated Zynyz or placebo in combination with platinum-based chemotherapy (carboplatin and paclitaxel) in adult patients with metastatic or inoperable locally recurrent SCAC not previously treated with systemic chemotherapy.

The study results demonstrated a statistically significant 37% reduction in the risk of progression or death. Patients treated with Zynyz achieved a median progression-free survival of 9.3 months, compared with 7.4 months for patients in the placebo combination group.

Improvements were also observed across secondary endpoints, including overall survival.

Importantly, the safety profile of the combination therapy was generally consistent with other PD-1 inhibitor and chemotherapy combinations.

The EC decision follows the positive Committee for Medicinal Products for Human Use (CHMP) opinion received from the European Medicines Agency in January 2026.

We note that the drug is already approved for the first-line treatment of adult patients with inoperable locally recurrent or metastatic SCAC in the United States and Japan. It is also approved as a single agent for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression or intolerance to platinum-based chemotherapy in the United States.

In addition, Zynyz is approved as a monotherapy for the first-line treatment of adults with metastatic or recurrent locally advanced merkel cell carcinoma in the United States, European Union, Canada and Switzerland.

The drug is marketed in the United States by Incyte. In 2017, the company entered into an exclusive collaboration and licensing agreement with MacroGenics for global rights to retifanlimab.

The POD1UM clinical program for retifanlimab includes POD1UM-303, POD1UM-202 and several other studies in different stages for patients with solid tumors.

INCY’s Efforts to Expand PortfolioIncyte’s efforts to develop new drugs to diversify its portfolio and add an incremental stream of revenues are impressive.

At present, lead drug Jakafi accounts for the lion’s share of revenues.

The lead drug, Jakafi, is a JAK1/JAK2 inhibitor approved for the treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea; intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF in adults; steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older; and chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients aged 12 years and older.

Sales in all indications continue to be strong and should maintain momentum going forward.

Jakafi is marketed by Incyte in the United States and by Novartis (NVS - Free Report) as Jakavi in ex-U.S. markets.

Incyte earns product royalty revenues from Novartis for the commercialization of Jakavi in ex-U.S. markets.

Encouraging uptake of new drugs like Pemazyre, Monjuvi and Tabrecta contributes to its top-line growth.

Incyte also receives royalties from the sales of Tabrecta (capmatinib), which is approved for treating adult patients with metastatic non-small cell lung cancer. Novartis has exclusive worldwide development and commercialization rights to Tabrecta.

The pipeline progress is impressive as well. Incyte expects to have 14 pivotal clinical trials underway by year-end.

INCY’s Zacks Rank & Stocks to ConsiderINCY currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the drug/biotech sector are Catalyst Pharmaceuticals (CPRX - Free Report) and ANI Pharmaceuticals (ANIP - Free Report) . While Catalyst Pharmaceuticals currently sports a Zacks Rank #1 (Strong Buy), ANI Pharmaceuticals holds a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have increased from $2.53 to $2.82, and the same for 2027 have grown from $2.85 to $3.20. CPRX’s shares have risen 17% in the past year.

Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.

Over the past 60 days, estimates for ANI Pharmaceuticals’ 2026 earnings per share have increased from $8.20 to $9.00, while the same for 2027 have risen from $9.25 to $10.10. ANIP’s shares have gained 25.9% in the past year.

ANI Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 22.21%.

New York, New York--(Newsfile Corp. - March 9, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Grocery Outlet Holding Corp. ("Grocery Outlet Holding Corp.") (NASDAQ: GO) concerning potential violations of the federal securities laws.

On the Q3 2025 earnings call on November 4, 2025, management narrowed the FY2025 comparable-store sales outlook to 0.6%-0.9%, down from 0.6%-1.2%. Management nevertheless reiterated confidence in the outlook for gross margin, adjusted EBITDA and adjusted EPS.

Months later, the Company announced plans to close 36 under-performing stores, approximately 6% of the Company's total store base - in connection with its March 2026 earnings release. The closure plan had not been referenced during the Q3 2025 earnings call or in the Company's December 3, 2025 Form 8-K, which stated the Company was "not otherwise providing any update regarding its outlook issued on November 4, 2025." The same earnings release also introduced FY2026 guidance significantly below analyst expectations.

If you suffered a loss on your Grocery Outlet Holding Corp. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212)363-7500
Fax: (212)363-7171

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/287778

Source: Levi & Korsinsky, LLP

American Tower Corporation (AMT) Presents at Deutsche Bank 34th Annual Media, Internet & Telecom Conference Transcript

Bentley Systems, Incorporated (BSY - Free Report) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earnings estimates for the company.

Analysts' growing optimism on the earnings prospects of this company is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- has this insight at its core.

The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.

For Bentley Systems, Incorporated, there has been strong agreement among the covering analysts in raising earnings estimates, which has helped push consensus estimates considerably higher for the next quarter and full year.

The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:

12 Month EPS

Current-Quarter Estimate RevisionsThe company is expected to earn $0.38 per share for the current quarter, which represents a year-over-year change of +8.6%.

Over the last 30 days, the Zacks Consensus Estimate for Bentley Systems has increased 7.44% because three estimates have moved higher compared to no negative revisions.

Current-Year Estimate RevisionsThe company is expected to earn $1.42 per share for the full year, which represents a change of +17.4% from the prior-year number.

In terms of estimate revisions, the trend for the current year also appears quite encouraging for Bentley Systems. Over the past month, four estimates have moved higher compared to no negative revisions, helping the consensus estimate increase 6.74%.

Favorable Zacks RankThe promising estimate revisions have helped Bentley Systems earn a Zacks Rank #2 (Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.

Bottom LineInvestors have been betting on Bentley Systems because of its solid estimate revisions, as evident from the stock's 20% gain over the past four weeks. As its earnings growth prospects might push the stock higher, you may consider adding it to your portfolio right away.

SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is notifying investors that a securities class action lawsuit has been filed against Corcept Therapeutics Inc. (NASDAQ: CORT) and certain of its top executives. The lawsuit, Allegheny County Employees' Retirement System v. Corcept Therapeutics Incorporated, No. 26-cv-01525 (N.D. Cal.), seeks to recover losses for investors who purchased CORT common stock between October 31, 2024, and December 30, 2025.

The firm urges Corcept investors who suffered significant losses to contact the firm now to discuss their rights.

The complaint alleges that Corcept misled the market regarding the regulatory viability of its lead product candidate, relacorilant. While the company publicly claimed the drug was supported by "powerful evidence" and was "approaching approval," the lawsuit reveals that the FDA had reportedly warned Corcept “on several occasions” during pre-submission meetings that its clinical data was inadequate.

Investors who suffered substantial losses are encouraged to visit the Hagens Berman’s CORT Case Page to download a copy of the complaint and review the lead plaintiff process: www.hbsslaw.com/cases/corcept  

“The litigation targets the alleged gap between Corcept’s ‘high confidence’ narrative and the private warnings from the FDA,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation. “The complaint alleges that management knew the FDA had warned them to expect ‘significant review issues’ if they filed the NDA, yet they chose to move forward while assuring investors that no impediments existed.”

Summary of the Allegations: The Relacorilant Rejection

The filed complaint alleges that Corcept and its executives violated the Securities Exchange Act of 1934 by making false and/or misleading statements.

Concealed FDA Concerns: The lawsuit alleges that during pre-submission meetings, the FDA explicitly informed Corcept of concerns regarding the adequacy of the clinical development program to assess relacorilant’s effect on hypertension.The “Warning Not to File”: Evidence cited in the complaint suggests the FDA warned the company to expect rejection if it submitted the NDA without additional evidence of effectiveness—a warning allegedly withheld from shareholders.The December 31 “Surprise”: On December 31, 2025, Corcept revealed it had received a Complete Response Letter (CRL) from the FDA. The news caused CORT shares to plummet from $70.20 to **$34.80** in a single day, erasing over $3.6 billion in market value.The Post-Class Period Disclosure: A subsequent redacted copy of the CRL published on January 30, 2026, confirmed that the FDA had concluded it could not arrive at a "favorable benefit-risk assessment" without further effectiveness data. View our latest video summary of the allegations: youtube.com/watch?v=vMk3jcOV3Ng

Critical Deadline: April 21, 2026

If you purchased Corcept common stock during the Class Period, you have until April 21, 2026, to ask the Court to appoint you as Lead Plaintiff.

If you invested in Corcept and have substantial losses, or have knowledge that may assist the firm’s investigation,

SUBMIT YOUR CORT LOSSES NOWContact: Reed Kathrein at 844-916-0895 or email [email protected] If you’d like more information and answers to other frequently asked questions about the Corcept case and our investigation, read more »

Whistleblowers: Persons with non-public information regarding Corcept should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Contact:
Reed Kathrein, 844-916-0895

NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns issuer and senior unsecured debt ratings of A- to Takeoff Merger Sub Inc. (“Merger Sub”), an entity which will merge with Air Lease Corporation (NYSE: AL or “Air Lease”, a global aircraft leasing company based in Los Angeles, California) and be renamed Sumisho Air Lease Corporation (“SALC” or the company). The rating Outlook is Stable. KBRA expects to assign an A- rating to the senior unsecured notes expected to be issued by Merger Sub. Upon close of the.

March 09, 2026 12:04 ET  | Source: Surgery Partners, Inc.

BRENTWOOD, Tenn., March 09, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), is scheduled to meet with investors at the Barclays 28th Annual Global Healthcare Conference, including a presentation on Tuesday, March 10, 2026, at 2:30 p.m. (Eastern Time).

Interested investors and other parties may listen to a simultaneous webcast of the event through the investor relations section of the company's website at www.surgerypartners.com. The replay will also be available on this same website for a limited time following the call.

To learn more about Surgery Partners, please visit the Company's website at www.surgerypartners.com. Surgery Partners uses its website as a channel of distribution for material Company information. Financial and other material information regarding Surgery Partners is routinely posted on the Company's website and is readily accessible.

About Surgery Partners

Headquartered in Brentwood, Tennessee, Surgery Partners is a leading healthcare services company with a differentiated outpatient delivery model focused on providing high quality, cost effective solutions for surgical and related ancillary care in support of both patients and physicians. Founded in 2004, Surgery Partners is one of the largest and fastest growing surgical services businesses in the country, with more than 200 locations in 30 states, including ambulatory surgery centers, surgical hospitals, multi-specialty physician practices and urgent care facilities. For additional information, visit www.surgerypartners.com.

Contact:

Surgery Partners Investor Relations
(615) 234-8940
[email protected]

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

TrendForce, which tracks global smartphone shipments and production, reports that Samsung’s production matched Apple’s (NASDAQ: AAPL | AAPL Price Prediction) last year. Total global smartphones reached 1.25 billion across the industry.

Apple and Samsung tied with production numbers of 239.8 million. For the year, Apple’s number rose 9% and Samsung’s by 11%. Apple’s newest product was the primary reason it did so well. “In 2025, the iPhone 17 series benefited from well-positioned retail pricing to deliver strong market performance.” Apple made a phenomenal run at the end of the year. In the fourth quarter, production rose 54% to 87 million units.

Chinese manufacturers have done well in recent years because it is the world’s largest smartphone market, with about 1 billion wireless subscribers. However, the run mostly ended last year. Market leader Xiaomi saw a 7% drop to 169.8 million. Vivo’s sales dropped 17% to 102 million. Honor was the exception with an increase of 16% to 70.5 million

Apple’s success came as a surprise to some people. It did not launch a much-anticipated AI version of its iOS software. It pushed that into 2026. Soon, its upgraded Siri AI product will be released, powered by Google’s Gemini. CNBC reported that “Apple has picked Google’s Gemini to run AI-powered Siri coming this year.”

Apple’s iPhone 17 sales drove an extremely strong quarter. In its most recent report, iPhone revene reached $85.3 billion, up from $69.1 billion in the same period a year ago. Total revenue was $143.6 billion, so iPhone sales were 59% of total revenue.

If Apple did so well without an AI product, imagine how well it will do with one?

NEW YORK--(BUSINESS WIRE)--Monomoy Capital Partners, a private investment firm focused on private equity and credit investing in the middle market, announced today it has entered into a definitive agreement to acquire the leading quick lube and automotive service franchisor in North America, Jiffy Lube International, Inc., from Pennzoil Quaker State Company DBA SOPUS Products, a wholly owned subsidiary of Shell USA, Inc. An affiliate of Monomoy will acquire Jiffy Lube through its Fund V for app.

Eltek Ltd. (ELTK) Q4 2025 Earnings Call March 9, 2026 9:30 AM EDT

Company Participants

Eli Yaffe - Chief Executive Officer
Ron Freund - Chief Financial Officer

Conference Call Participants

Mark Sharogradsky

Presentation

Operator

Ladies and gentlemen, thank you for standing by. Welcome to the Eltek Ltd. 2025 Annual and Fourth Quarter Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. Before I turn over the call to Mr. Eli Yaffe, Chief Executive Officer; and Ron Freund, Chief Financial Officer, I'd like to remind you that they will be referring to forward-looking information in today's presentation and in the Q&A. By its nature, this information contains forecasts, assumptions, and expectations about future outcomes, which are subject to the risks and uncertainties outlined here and discussed more fully in Eltek's public disclosure filings.

These forward-looking statements are projections and reflect the current beliefs and expectations of the company. Actual events or results may differ materially. We'll also be referring to non-GAAP measures. Eltek undertakes no obligation to publicly release revisions to such forward-looking statements to reflect events or circumstances occurring subsequent to this date.

I will now turn the call over to Mr. Eli Yaffe. Mr. Yaffe, please go ahead.

Eli Yaffe
Chief Executive Officer

Thank you. Good morning. Thank you for joining us for our 2025 annual earnings call. With me is Ron Freund, our Chief Financial Officer. We will begin by providing you with an overview of our business and summary of the principal factors that affected the results during 2025. After our prepared remarks, we'll be happy to answer any of your questions. By now, everyone should have access to our press release, which was released earlier today. The release was also available on our website. Revenue for 2025 totaled $51.8 million, representing an 11% increase compared to 2024. This growth reflects the company's strategic accelerated investment program, which

Calgary, Alberta--(Newsfile Corp. - March 9, 2026) - Wilton Resources Inc.  (TSXV: WIL) (the "Corporation") announces that it intends to: (i) amend the expiry date of 833,333 outstanding common share purchase warrants that were granted pursuant to a private placement of units of the Corporation which closed on May 23, 2024 (the "May 23 Warrants"); and (ii) amend the expiry date of 2,791,767 outstanding common share purchase warrants that were granted pursuant to a private placement of units of the Corporation which closed on May 28, 2024 (the "May 28 Warrants" and together with the May 23 Warrants, the "Warrants").

At the time of issuance, each May 23 Warrant entitled the holder to acquire one common share of the Corporation (the "Common Shares") at a price of $0.70 per Common Share, exercisable until May 23, 2025. On May 12, 2025, the Corporation extended the expiry date of the May 23 Warrants from May 23, 2025 to March 23, 2026. The Corporation proposes to further amend the May 23 Warrants by extending the expiry date by one year from March 23, 2026 to March 23, 2027. All other terms of the May 23 Warrants will remain unchanged.

At the time of issuance, each May 28 Warrant entitled the holder to acquire one Common Share at a price of $0.91 per Common Share, exercisable until May 28, 2025. On May 12, 2025, the Corporation extended the expiry date of the May 28 Warrants from May 28, 2025 to March 28, 2026. The Corporation proposes to further amend the May 28 Warrants by extending the expiry date by one year from March 28, 2026 to March 28, 2027. All other terms of the May 28 Warrants will remain unchanged.

The Warrants are not owned by, directly or indirectly, any of the Corporation's directors, officers or control persons.

The proposed amendments to the Warrants are subject to the approval of the TSXV.

FORWARD-LOOKING INFORMATION

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Corporation's current beliefs or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this press release contains forward-looking information with respect to the extension of the term of the Warrants. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Corporation. The material facts and assumptions include obtaining approval of the Exchange of the proposed extension of the term of the Warrants. The Corporation cautions the reader that the above list of risk factors is not exhaustive. The forward-looking information contained in this release is made as of the date hereof and the Corporation is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Due to the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward- looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

Additional information regarding the Corporation is available on the Corporation's profile on the SEDAR+ website at www.sedarplus.ca.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities Laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/287772

Source: Wilton Resources Inc.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

UNH faces rising medical costs, regulatory probes and a healthcare hiring slump while shares keep falling, leaving investors weighing risk or opportunity.

, /PRNewswire/ -- Residential Home Health, an affiliate of Graham Healthcare Group, announces the successful acquisition of Covenant Home Health of Havertown PA, a respected home health provider serving Bucks, Chester, Dauphin, Delaware, Lancaster, Lebanon, Montgomery, Philadelphia, and York counties. The combination strengthens Residential's presence in Eastern Pennsylvania, extending its reach into Philadelphia and Delaware counties. The acquisition reflects Residential's commitment to growth rooted in quality, clinical excellence, and strong local leadership.

"Covenant's strong local relationships and skilled clinical teams strengthen our foundation in southeastern Pennsylvania," said Dee Grein, CEO, Graham Healthcare Group. "By combining our resources and expertise, we are positioned to expand our services across the region, bringing high-quality nursing and therapy services to more patients while preserving the personalized care both organizations are known for."

As the healthcare landscape continues to evolve, Residential remains focused on delivering measurable outcomes, strengthening community partnerships, and ensuring patients receive exceptional care from clinicians they know and trust.  Residential plans to retain Covenant's employees and is committed to ensuring a seamless transition for patients, families, referral partners, and staff. Current patients will experience no interruption in services.

About Graham Healthcare Group
Graham Healthcare Group (GHG) is a subsidiary of Graham Holdings Company (NYSE: GHC). GHG companies include Residential Home Health, Residential Hospice, Allegheny Health Network (AHN) Healthcare@Home, and Mary Free Bed at Home. GHG and its companies employ more than 3,000 dedicated professionals serving more than 20,000 patients daily. For more information, visit Graham Healthcare Group.

About Residential Home Health and Hospice
Residential Home Health and Hospice are leading providers of skilled home health, palliative, and hospice care in communities across Florida, Illinois, Kansas, Michigan, Missouri, Ohio, and Pennsylvania. Our experienced and professional care team members work with local physicians to deliver personalized in-home healthcare services for every stage of the patient's healthcare journey. For more information visit Residential Healthcare Group.

About Covenant Home Health
Covenant Home Health is a leading provider of skilled nursing, therapy, and supportive care services in Eastern Pennsylvania. Through personalized care plans, interdisciplinary collaboration, and a mission-driven culture, Covenant Home Health is focused on improving clinical outcomes and elevating the standard of care across the communities we serve. For more information visit Covenant Home Health.

A note about Covenant Private Duty. There will be no changes to Covenant Private Duty, its ownership, or offerings.

Ben Bogan and Ted Cohen of Stoneridge Partners served as the exclusive advisors to Covenant Home Health.

SOURCE Residential Home Health and Hospice

Attorneys general from several states say they haven’t abandoned their antitrust case against Live Nation.

This came after the news Monday (March 9) that the U.S. Department of Justice had reached a settlement with the company, which owns Ticketmaster.

As Reuters reported, Live Nation will pay a $200 million settlement and agree to make changes to its platform, such as allowing the participation of third-party ticketing services like Eventbrite.

However, New York State Attorney General Letitia James said her office could not agree to the settlement, arguing that it did not address the competition issue at the center of the case, and that it benefits Live Nation at the consumer’s expense.

“For years, Live Nation has made enormous profits by exploiting its illegal monopoly and raising costs for shows,” James said in a news release. “My office has led a bipartisan group of attorneys general in suing Live Nation for taking advantage of fans, venues, and artists, and we are committed to holding Live Nation accountable.”

She added that she and her colleagues from other states will continue to pursue their case.

We’d love to be your preferred source for news.

Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

Advertisement: Scroll to Continue

The Justice Department had filed suit in 2024 to break up Live Nation, claiming antitrust violations and monopolistic practices on the company’s part. The company had faced heavy scrutiny since acquiring Ticketmaster in 2010.

Then came Taylor Swift’s “Eras” tour, where fans of the pop star spent hours in online queues to access the high-priced tickets.

Fans of Swift and other musicians sued Live Nation and Ticketmaster in 2024, accusing the companies of colluding with other organizations to drive up the price of tickets.

“This lawsuit is based on false assumptions about how ticketing works. Artist teams, not Ticketmaster, set prices,” a Live National spokesperson told Wired at the time. “Live Nation does not own stadiums in the U.S. and primary tickets are consistently priced below market value, as evidenced by resale prices averaging more than double.”

The Justice Department and Live Nation had been weeks into their antitrust trial when the settlement was announced.

According to Reuters, U.S. District Judge Arun Subramanian questioned on Monday why the two sides had not notified the court about the settlement sooner, as the agreement was signed last week. A lawyer for the DOJ told the judge she was unaware of the settlement as the trial continued on Friday. The judge was unhappy with the outcome, the report added.

“It shows absolute disrespect for the court, for the jury, for this entire process, and it is entirely unacceptable,” Subramanian said.

VANCOUVER, BC / ACCESS Newswire / March 9, 2026 / Alta Copper Corp. (TSX:ATCU)(OTCQX:ATCUF)(BVL:ATCU) ("Alta Copper") and Nascent Exploration Pty Ltd are pleased to announce the successful completion of the previously announced plan of arrangement under Division 5 of Part 9 of the Business Corporations Act (British Columbia) (the "Arrangement").

Pursuant to the Arrangement, Nascent Exploration Pty Ltd ("Nascent"), a wholly-owned subsidiary of Fortescue Ltd ("Fortescue"), acquired all of the issued and outstanding common shares of Alta Copper (the "Alta Copper Shares") not already held by Nascent and in exchange holders of the Alta Copper Shares ("Alta Copper Shareholders") received C$1.40 in cash per Alta Copper Share , the holders (the "Optionholders") of options to purchase Alta Copper Shares (the "Alta Copper Options") received C$1.40 less the applicable exercise price, per underlying share, for Alta Copper Options held and holders of the deferred share units of Alta Copper (the "Alta Copper DSUs") and restricted share units of Alta Copper (the "Alta Copper RSUs") received C$1.40 per underlying share, for the Alta Copper DSUs and the Alta Copper RSUs, held immediately prior to the effective time of the Arrangement (the "Consideration"). The implied equity value of the Arrangement is approximately C$139 million.

As a result of the completion of the Arrangement, the Alta Copper Shares are expected to be delisted from the Toronto Stock Exchange on or about March 10, 2026 (the "Delisting"). The Alta Copper Shares will correspondingly be withdrawn from the Bolsa de Valores de Lima ("BVL") exchange and the OTC Markets Group ("OTCQX") trading platform. In connection with the Delisting, Alta Copper will also submit an application to the applicable securities regulators to cease to be a reporting issuer and to terminate its public reporting obligations in Canada. Further details regarding the Arrangement are set out in Alta Copper's management information circular dated December 19, 2025, (the "Circular") a copy of which is available under Alta Copper's issuer profile on SEDAR+ at www.sedarplus.ca.

Alta Copper Shareholders are reminded to review the Circular in respect of the procedure for receiving the Consideration for their Alta Copper Shares. Registered shareholders (Alta Copper Shares held in physical form or a direct registration system ("DRS") advice) must complete, sign and return the letter of transmittal, along with their share certificate(s) or DRS advice(s), to TSX Trust Company, the depositary for the Arrangement. Non-registered shareholders (Alta Copper Shares held with a broker, bank or other intermediary) should contact their intermediaries for instructions and assistance in receiving the Consideration for such Alta Copper Shares. The letter of transmittal is available at https://altacopper.com/investors/shareholders-meetings/ or under Alta Copper's profile on SEDAR+ (www.sedarplus.ca).

Early Warning Disclosure

Pursuant to the requirements of National Instrument 62-104 - Take-Over Bids and Issuer Bids and National Instrument 62-103 - The Early Warning System and Related Take-Over Bid and Insider Reporting Issues, Nascent will file an early warning report (the "Early Warning Report") in accordance with applicable securities laws. Further information and a copy of the Early Warning Report may also be obtained by contacting Nascent at the contact information below. The head office of Nascent is located at Ground Floor 256 St Georges Terrace, Perth, WA, Australia 6000.

Immediately prior to closing of the Arrangement, Nascent and its affiliates held 33,638,304 Alta Copper Shares, representing approximately 35.70% of the outstanding Alta Copper Shares immediately prior to closing of the Arrangement. Pursuant to the Arrangement, Nascent acquired an aggregate of 60,573,822 Alta Copper Shares, thereby increasing its holdings of Alta Copper Shares to 100%. Upon completion of the Arrangement, Alta Copper became a wholly-owned subsidiary of Nascent. In exchange for the Alta Copper Shares, Nascent paid C$1.40 to holders of the Alta Copper Shares per Alta Copper Share held, the Optionholders C$1.40 less the applicable exercise price, per underlying share, for the Alta Copper Options held and the holders of the Alta Copper DSUs and the Alta Copper RSUs C$1.40 per underlying share, for the Alta Copper DSUs and the Alta Copper RSUs held, for an aggregate consideration of C$89,079,378.18.

Nascent acquired the Alta Copper Shares pursuant to the Arrangement and intends for Alta Copper to cease to be a reporting issuer in all jurisdictions of Canada and remain a wholly-owned subsidiary of Nascent.

About Alta Copper

Alta Copper is focused on the development of its 100% owned Cañariaco advanced-staged copper project. Cañariaco comprises 91 square km of highly prospective land located 102 km northeast of the City of Chiclayo, Peru, which includes the Cañariaco Norte deposit, the Cañariaco Sur deposit and the Quebrada Verde prospect, all within a 4 km NE-SW trend in northern Peru's prolific mining district.

Information contact

Alta Copper
Giulio T. Bonifacio, President and Chief Executive Officer
Direct: +1 604 318 6760
Email: [email protected]
https://altacopper.com/

Nascent
Phone: 1800 134 442
Email: [email protected]

Forward-looking statements

This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements.

In this news release, forward-looking statements relate to, among other things, statements regarding: the completion of the Delisting and the timing thereof; the submission of the cease to be a reporting issuer application by Alta Copper; the filing of the Early Warning Report; and the intention for Alta Copper to remain a wholly-owned subsidiary of Nascent. These forward-looking statements are no guarantees of future results and involve risks and uncertainties that may cause actual results to differ materially from the potential results discussed in the forward-looking statements.

In respect of the forward-looking statements, Alta Copper, Fortescue and Nascent have relied on certain assumptions that they believe are reasonable at this time, including, but not limited to, assumptions concerning Alta Copper, Fortescue, Nascent and the Arrangement, including the anticipated benefits therefrom. Events or circumstances may cause actual results to differ materially from those predicted as a result of numerous known and unknown risks, uncertainties, and other factors.

Risks and uncertainties that may cause such differences include but are not limited to: the possibility that the Alta Copper Shares will not be delisted from the Toronto Stock Exchange, the OTCQX or the BVL exchange within the timing currently contemplated or at all; that Alta Copper's application for an order to cease to be a reporting issuer (or equivalent) in each of the provinces and territories of Canada may not be accepted or may be delayed; and such other risk factors identified under the "Risk Factors" section in the Circular, a copy of which is available under Alta Copper's issuer profile on SEDAR+ at www.sedarplus.ca. These factors are not intended to represent a complete list of the factors that could affect Alta Copper, Fortescue and Nascent. However, such risk factors should be considered carefully. There can be no assurances that such estimates and assumptions will prove to be correct. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release concerning these times. Each of Alta Copper, Fortescue and Nascent are under no obligation (and expressly disclaims any such obligation) to update or alter any statements containing forward-looking information or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. All of the forward-looking information in this release is qualified by the cautionary statements herein.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this news release.

SOURCE: Alta Copper Corp.

Seneca Foods Corporation remains a soft "Buy" after a 46.7% rally since June 2023, outperforming the S&P 500. SENEA's Q3 FY2026 saw revenue rise to $508.3 million and adjusted net profit surge from $22.9 million to $42.8 million, driven by margin expansion. Valuation remains attractive both on an absolute and relative basis, with only one peer trading cheaper on forward multiples.

Impala Platinum Holdings Limited (IMPUY) Q2 2026 Earnings Call March 4, 2026 7:00 PM EST

Company Participants

Nicolaas Muller - CEO & Executive Director
Patrick Morutlwa - Group Chief Operating Officer
Meroonisha Kerber - CFO, Debt Officer & Executive Director
Sifiso Sibiya - Group Executive of Refining & Marketing

Presentation

Nicolaas Muller
CEO & Executive Director

Welcome to the webcast presentation of our results for the Half Year Ended 31 December 2025. I am Nico Muller, the CEO of Impala's. This presentation provides a high-level overview of our group's performance over the first half of the financial year. Before we begin, I draw your attention to our normal disclosure statement pertaining to any forward-looking statements that may be made today.

I will start today's presentation with an overview of the group's performance and the key features. This will lead into an account of the group's operational performance presented by Patrick Morutlwa, our Chief Operating Officer; followed by the financial results presented by Meroonisha Kerber, our Chief Financial Officer; and then Sifiso Sibiya, our Group Executive for Refining and Marketing, will provide an overview of the PGM markets before I finish off with our key focus areas and the outlook for the remainder of financial year 2026.

We continue to strengthen our commitment to a safety-first culture at all our operations, and we remain deeply committed to the well-being of our employees. The group's strategic safety program continued to advance during this period with a steady progress recorded across all operations. Compliance with critical safety behaviors continues to vary, underscoring the need to further embed consistent, safe operating practices.

We are pleased to report that no fatal incidents were reported at group mining and processing operations in the 6-month period. Regrettably, however, an employee at Impala Rustenburg was fatally injured in a motor vehicle accident in December

Philadelphia, Pennsylvania--(Newsfile Corp. - March 9, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) ("Ultragenyx" or the "Company") on behalf of investors who purchased Ultragenyx common stock during the period from August 3, 2023 through December 26, 2025 (the "Class Period").

Investor Deadline: Investors who purchased Ultragenyx common stock during the Class Period may, no later than April 6, 2026, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.

Ultragenyx is a biopharmaceutical company that acquires and develops novel products for treatment of rare genetic diseases. It is headquartered in Novato, Calif.

According to the lawsuit, throughout the Class Period, defendants issued overwhelmingly positive statements to investors concerning the ORBIT and COSMIC Phase 3 programs, clinical trials to test setrusumab as a treatment for Osteogenesis Imperfecta.

When, on December 29, 2025, Ultragenyx disclosed that neither study achieved its primary endpoint of reducing the annualized clinical fracture rate, the price of its shares dropped more than 42%, from a closing price of $34.19 per share on December 26, 2025 to a close of $19.72 per share on December 29, 2025.

If you are a Ultragenyx investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at [email protected] or (215) 875-3015, or Caitlin Adorni at [email protected] or (267)764-4865.

About Berger Montague

Berger Montague is one of the nation's preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE.

For more information or to discuss your rights, please contact:

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/286672

Source: Berger Montague

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against Navan, Inc. (NASDAQ: NAVN), its IPO underwriters, and certain executives after the company’s December 15, 2025 announcement of Q3 2026 quarterly financial results for the quarter ended October 31, 2025. Among other matters, investors learned that Navan incurred a huge sequential increase in sales and marketing expenses.

Of concern was that the quarter end coincided with Navan’s IPO closing, whereby the company and certain selling stockholders sold about 36.9 million shares at $25 per share to the investing public.

Navan also announced the surprise departure of its CFO (Amy Butte) effective January 9, 2026.

The markets swiftly reacted, sending the price of Navan shares down nearly 12% to close at $12.90, or about 48% below the IPO price, on December 16. By the time the complaint was filed on February 23, 2026, the price of Navan shares closed at $9.16, or 63% below the IPO price.

The developments and severe market reactions have prompted national shareholder rights law firm Hagens Berman to investigate the legal claims that Navan and the other defendants violated the federal securities laws. The firm urges Navan investors who suffered significant losses to contact the firm now to discuss their rights.

Navan, Inc. (NAVN) Securities Class Action: 

The litigation challenges Navan’s alleged omissions from its IPO offering documents, including adverse, then-existing trends in sales and marketing expenses.

The complaint alleges that Navan’s IPO offering documents offered a picture of potential growth by emphasizing that its business “experienced rapid growth,” and its solutions catered to “customers of all sizes across any industry vertical.” The IPO documents stated Navan’s revenue “grew 33% year-over-year” from 2024 to 2025, its gross booking volume (“GBV”) “grew 32% year-over-year” during the same timeframe, and its “usage yield” was “approximately 7%” in each of those years as well.

But, when on December 15, 2025, Navan unexpectedly reported a 39% sequential spike in its sales and marketing expenses during the IPO-coincident quarter ended October 31, 2025, slowing year-over-year revenue growth, and a fourfold year-over-year increase in its GAAP net loss, questions arose about the sufficiency of Navan’s disclosures, including those related to its Q3 expense trends, while conducting its IPO.

The complaint alleges that Navan’s and the other defendants’ statements and omissions during the IPO misled investors because crucial information – including the spike in sales and marketing expenses – was not included in the company’s offering documents.

“We’re investigating whether, at the time of its IPO, Navan was legally transparent about apparently known, materially adverse trends in its business. We’re also investigating the circumstances surrounding the CFO’s abrupt departure,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

If you invested in Navan and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to additional frequently asked questions about the case and the firm’s Navan investigation, read more »

Whistleblowers: Persons with non-public information regarding Navan should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Contact:
Reed Kathrein, 844-916-0895

2.75K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Key Takeaways Trade Desk says video, including CTV, made up about half of its business in Q4 as streaming ad demand grows.TTD platform evaluates roughly 20 million ad opportunities per second to select impressions.Trade Desk launched the Ventura Ecosystem in February to improve transparency and efficiency in streaming ads. The Trade Desk, Inc.’s (TTD - Free Report) connected TV (CTV) platform is increasingly positioned to capture premium streaming advertising budgets as advertisers shift toward programmatic, decision-based buying models. The company emphasized that CTV remains one of its fastest-growing channels, with video, which includes CTV, accounting for about half of its business in the fourth quarter of 2025. The growth reflects a broader industry transition as major content owners expand programmatic access to their premium streaming inventory.

The evolution of CTV advertising is being driven by a structural shift away from traditional buying approaches such as insertion orders and fixed programmatic guarantees. Instead, advertisers are increasingly favoring biddable transactions that allow them to apply data-driven decision-making in real time. This shift enables brands to evaluate large volumes of potential ad opportunities and select the impressions most likely to drive campaign outcomes.

Management highlighted that the open Internet now offers more advertising supply than ever before, creating a buyer’s market for advertisers. In such an environment, platforms capable of objective decision-making across large volumes of impressions become increasingly valuable. The company highlighted that its platform evaluates roughly 20 million ad opportunities every second, using extensive data inputs to determine which impressions should be purchased for advertisers.

A key differentiator for the platform is that Trade Desk does not own media inventory. This structure allows the system to prioritize objective decision-making rather than steering advertisers toward owned inventory. By evaluating impressions across a wide range of publishers and streaming environments, the platform aims to identify the most relevant and effective opportunities for campaign performance.

The company also stated that many sophisticated advertisers are seeking ways to maintain the advantages of negotiated deals while preserving decisioning flexibility. Instead of committing to fixed placements, advertisers increasingly prefer frameworks that allow them to bid across available inventory while still benefiting from negotiated pricing or scale-based advantages. As a result, the market is moving toward more biddable CTV transactions that retain programmatic optimization.

In February 2026, Trade Desk expanded its push to reshape CTV advertising with the launch of the Ventura Ecosystem, an industry-wide collaboration built to foster greater transparency, fairness and revenue efficiency in streaming.

For the first quarter of 2026, the company expects revenue of at least $678 million, indicating year-over-year growth of about 10%. It also anticipates adjusted EBITDA of approximately $195 million for the quarter.

Taking a Look at CTV Efforts of PUBM & MGNIPubMatic, Inc.’s (PUBM - Free Report) CTV remains one of its most important growth channels. The company recently added a new marquee global streamer to its platform and has partnered with 28 of the top 30 global streaming services, including Roku, Samsung TV Plus, DirecTV, Fox Sports, Tubi and Vizio. Management stated that this leadership in the CTV ecosystem continues to attract leading global brands to its platform. Sony Network Communications recently selected PubMatic to reach both linear and CTV audiences programmatically through the company’s platform. The campaign demonstrates how PubMatic enables brands to connect with incremental customers while supporting stronger monetization opportunities for CTV publishers through programmatic execution across both linear and connected TV formats.

Magnite, Inc. (MGNI - Free Report) is seeing a significant inflection in the growth of the programmatic CTV market, reflected in 32% top-line growth excluding political spending in the fourth quarter, along with continued strength entering the first quarter. Management highlighted that advertising spend is increasingly shifting into CTV from multiple areas of digital advertising, including DV+. Management noted that in the first quarter, CTV already accounts for close to 50% of the company’s business. The company stated that Magnite’s technology, partnerships, trust and team position it to emerge as a key player in the CTV market. It also highlighted that the company’s CTV momentum is broad-based across both media owners and CTV ad buyers.

TTD Price Performance, Valuation and Estimates

Shares of TTD have gained 4.1% in the past month against Internet – Services industry’s decline of 6%.

Image Source: Zacks Investment Research

In terms of forward price/earnings, TTD’s shares are trading at 22.13X, lower than the Internet Services industry’s 24.88X.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for TTD’s earnings for 2026 has been revised downward over the past 30 days.

Image Source: Zacks Investment Research

TTD currently carries a Zacks Rank #3 (Hold).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against Apollo Global Management (NYSE: APO) and certain current and former executives after blockbuster reporting by The Financial Times and CNN on previously undisclosed information about Apollo’s business relationship with disgraced financier and sex offender Jeffrey Epstein. The lawsuit seeks to represent investors who purchased or otherwise acquired Apollo securities between May 10, 2021 and February 21, 2026.

Each of FT’s and CNN’s reports drove the price of Apollo shares significantly lower, prompting national shareholder rights law firm Hagens Berman to continue its investigation into claims that Apollo violated the federal securities. The firm urges Apollo investors who suffered significant losses to contact the firm now to discuss their rights.

Apollo Global Management (APO) Securities Class Action: 

The litigation is focused on the propriety of Apollo’s assurances that it had never done business with Epstein.

In contrast to Apollo’s assurances, the lawsuit alleges, among other things, that Apollo’s CEO Marc Rowan consulted Epstein on Apollo’s tax affairs.

This information came to light beginning on February 1, 2026, when the FT reported that “[t]op Apollo Global Management executives including chief Marc Rowan held wide-ranging discussions over the firm’s tax arrangements with Jeffrey Epstein throughout the 2010s, despite the private capital firm having previously said it ‘never did any business’ with the child sex offender.” The report was based on a review of millions of emails recently released by the U.S. Department of Justice.

Scrutiny heightened on February 17, 2026, when the FT reported that two teachers’ unions whose members have over $27.5 billion in capital commitments to Apollo funds requested an SEC investigation into Apollo’s “‘lack of candour’ over its ties to Epstein.” According to the article, the unions said in their letter to the SEC “‘[w]e are troubled by Apollo’s seeming inability to be forthcoming about the extent to which Epstein was a personal, social and professional associate of the firm and its partners.’”

The next day, Apollo’s President James C. Zelter sent a letter to clients and partners claiming there was nothing new in the Epstein documents and “[n]either Marc Rowan nor anyone else at Apollo (excluding Leon Black) had either a business or personal relationship with Jeffrey Epstein.”

Finally, on February 21, 2026, CNN published “How Wall Street’s Apollo got tangled up again in the Epstein files.” In addition to the above matters, CNN reported that “Eleanor Bloxham, founder and CEO of The Value Alliance Company, which advises boards and executives, told CNN that she believes the unions have a ‘strong case’ pushing for an SEC investigation[]” and “described Apollo’s response this week as ‘very weak’ and questioned why Rowan’s meetings and correspondence with Epstein was not previously disclosed.”

As these events have unfolded, by February 23, 2026, investors saw the price of Apollo shares fall over 15%, wiping out over $12 billion of market capitalization in just over three weeks.

“We’re investigating whether, having assured investors that it and no one else at Apollo except Black had ever done business with Epstein, Apollo misrepresented the reputational risk that it has apparently been facing for years,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

If you invested in Apollo and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to additional frequently asked questions about the case and the firm’s Apollo investigation, read more »

Whistleblowers: Persons with non-public information regarding Apollo should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Contact:
Reed Kathrein, 844-916-0895

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© Andrii Iemelianenko / Shutterstock.com

Retirees hunting for reliable income in 2026 keep landing on WisdomTree U.S. LargeCap Fund (NYSEARCA:EPS), a fund that does something different from most S&P 500 trackers. Rather than weighting companies by market capitalization, it weights them by earnings. Bigger earners get bigger allocations, tilting the portfolio toward profit-generating businesses rather than simply the most valuable ones.

How EPS Generates Its Income The fund passes through dividends from its large-cap U.S. equity holdings. Owning over 500 companies across every major sector means no single dividend cut can meaningfully derail the income stream. The 1.21% dividend yield is modest, reflecting the fund’s composition: its largest holdings are high-earning tech and growth companies that tend to retain earnings rather than distribute them.

The quarterly distribution history shows a consistent, if unspectacular, income track record. 2025 dividends ranged from $0.195 in Q1 to $0.245 in Q4, and the fund has maintained a quarterly payment schedule since its inception in February 2007, covering multiple recessions and market dislocations without skipping a payment.

Is the Income Stream Actually Safe? The earnings-weighted methodology provides structural income durability. Companies that earn more get more weight, naturally filtering toward businesses generating real cash. The 16% annual portfolio turnover keeps transaction costs low and tax drag minimal, both of which matter to retirees drawing income from a taxable account.

The macro backdrop is supportive. Total U.S. corporate profits reached $4,105.2 billion in Q3 2025, up 9.3% year-over-year, with financial sector profits growing sharply. Since EPS weights toward earnings, rising corporate profits directly strengthen the fund’s income foundation.

The honest caveat is the yield-versus-alternatives comparison. The 10-year Treasury currently yields 4.13%, well above EPS’s 1.21% dividend yield. That gap is real, and retirees who need current income above all else will feel it. What EPS offers in return is equity participation — the chance for both the income and the underlying portfolio to grow over time.

Total Return Puts the Yield in Context The total return data over longer horizons reflects both price appreciation and dividend income combined. EPS gained 16.88% over the past year and 81.83% over five years, demonstrating that the dividend alone understates the fund’s actual return. Year-to-date in 2026 the fund is slightly negative, down 1.31%, reflecting broader equity market softness.

Eighteen years of uninterrupted quarterly payments, broad diversification across 500+ companies, and an improving profit environment all support income continuity. Where EPS falls short for pure income investors is yield level, not yield safety. Retirees needing 3% or 4% in annual income will find this fund insufficient on its own. The fund’s structure is designed to serve as a broad equity holding, though its yield level remains below what dedicated income instruments offer.

SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman provides an update to investors in CoreWeave, Inc. (NASDAQ: CRWV) following the company’s dismal fourth-quarter 2025 financial results. The news follows allegations that the company concealed operational failures, as pled in a recently filed securities class action.

Hagens Berman is investigating the alleged claims in the pending suit. The firm urges investors who suffered substantial losses to:

SUBMIT YOUR LOSSES NOW

On February 26, 2026, CoreWeave reported a Q4 net loss of $452 million, or $0.89 per share—a staggering figure that nearly doubled the $0.49 loss per share anticipated by Wall Street analysts. Compounding the miss, CoreWeave issued a soft Q1 2026 revenue guidance of $1.9 billion to $2.0 billion, falling significantly short of the $2.3 billion consensus. On this news, CRWV shares plunged nearly 20%.

The disappointing Q4 results come after the filing of a securities class action suit against CoreWeave and certain of its executives arising from the company’s inability to scale its high-performance computing (HPC) clusters at the pace allegedly promised.

“We are investigating whether the company overstated scaling capabilities and hid critical delays,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation of the pending claims.

View our latest video summary of the allegations: youtube.com/watch?v=rWaDX1uGyJs

The CoreWeave, Inc. (CRWV) Securities Class Action

The pending securities class action, Masaitis v. CoreWeave, Inc., et al., No. 2:26-cv-00355, filed in the U.S. District Court for the District of New Jersey, seeks to recover losses for investors who acquired CoreWeave securities between March 28, 2025, and December 15, 2025 (the “Class Period”).

The complaint alleges that CoreWeave and its executives violated the Securities Exchange Act of 1934 by:

Overstating Scaling Capabilities: Allegedly misrepresenting the company's ability to satisfy "unprecedented" demand for its NVIDIA-powered AI cloud.Concealing Critical Delays: Failing to disclose that the Denton, Texas data center cluster—intended to service OpenAI—was months behind schedule due to weather and design plan revisions.Single-Supplier Dependency: Understating the operational and financial risks of its heavy reliance on a single third-party data center developer.Share Price Erosion: Since these infrastructure failures began to surface in late 2025, CoreWeave’s stock has faced severe downward pressure, further exacerbated by the latest Q4 earnings shock. Critical Deadline: March 13, 2026

If you purchased CoreWeave common stock during the Class Period (Mar. 28, 2025 – Dec. 15, 2025) and suffered substantial losses, you have until March 13, 2026, to ask the Court to appoint you as Lead Plaintiff.

TO SUBMIT YOUR COREWEAVE (CRWV) INVESTMENT LOSSES NOW, PLEASE USE THE SECURE FORM BELOW:

Report your CRWV Investment Losses to Hagens Berman NowContact: Reed Kathrein at 844-916-0895 or email [email protected] If you’d like more information and answers to frequently asked questions about the CoreWeave case and our investigation, read more »

Whistleblowers: Persons with non-public information regarding CoreWeave should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Contact:
Reed Kathrein, 844-916-0895

Conflict in Iran is spooking global markets, sending oil prices higher. Some geopolitical experts and professional investors are speculating that prolonged conflict there or a traditional boots-on-the-ground military campaign could send crude price soaring to $150 per barrel.

That would send shockwaves throughout the global economy, but it could also bring opportunity for headline-driven traders with a variety of leveraged ETFs, including the Direxion Daily Energy Bull 3X Shares (ERX) and the Direxion Daily Energy Bear 2X Shares (ERY). Those ETFs are linked to the equity-based Energy Select Sector Index and both are worth monitoring over the near-term.

“A prolonged war could lead to a spike in energy prices to over $100 per barrel and inflation,” observed Morningstar’s Leslie Norton on March 6, 2026.

ERX and other bullish oil strategies, including the Direxion Daily S&P Oil & Gas Exploration & Production Bull 2X ETF (GUSH), could benefit from near-term pops in oil prices, but if those prices remain high for what market participants consider to be too long, renewable energy could come back into focus. In turn, the bearish ERY could benefit.

“Elevated oil prices open opportunities to accelerate energy independence and increase the use of renewables throughout the United States,” added Norton.

Individual Equity Ideas Not surprisingly, geopolitical headlines stemming from the Middle East encourage some market participants to examine individual oil stocks.

It’s a practical response, and one that could put geared ETFs such as the the Direxion Daily XOM Bull 2X Shares (XOMX) and the Direxion Daily XOM Bear 1X Shares (XOMZ) in focus. Shares of Exxon dithered for much of last week, and that could be a sign the bearish XOMZ is worth monitoring over the near-term. The reasoning is twofold.

First, integrated oil stocks such as Exxon spent the first two months of 2026 rallying prior to the Iran headlines. Second, three-figure oil prices isn’t good news for producers, because it damps demand.

Traders considering XOMX and XOMZ obviously need to stay abreast of goings on in Iran, but they shouldn’t ignore Venezuela as a potential catalyst. At a recent Morgan Stanley conference, Senior Vice ​President Jack Williams said Exxon is preparing to send a team to Venezuela, home to the world’s largest crude reserves, to evaluate potential opportunities there.

For more news, information, and strategy, visit the Leveraged & Inverse Content Hub

Earn free CE credits and discover new strategies